Plant Name: Lamprocapnos spectabilis
Taxonomic Information:
Plant ID: NPO17796
Plant Latin Name: Lamprocapnos spectabilis
Taxonomy Genus: Lamprocapnos
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
54415
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD1; | |
| MTOR; | |
| TP53; | |
| SLC10A1; | |
| SMN1;SMN2; | |
| THPO; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| SLC superfamily of solute carriers | SLC10A1 | Bile acid transporter | Q14973 | CHEMBL5287 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.745E-09 | 5.978E-05 | CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.924E-06 | 2.095E-02 | CYP1A2, CYP2C19, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 6.182E-06 | 3.365E-02 | CYP1A2, CYP2D6 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.940E-05 | 3.382E-02 | CYP1A2, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.940E-05 | 3.382E-02 | CYP1A2, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0004497; monooxygenase activity | 1.848E-05 | 3.382E-02 | CYP1A2, CYP2C19, CYP2D6 |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 1.940E-05 | 3.382E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 2.292E-05 | 3.382E-02 | SMN1, SMN2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.511E-05 | 4.093E-02 | CYP1A2, CYP2C19, CYP2D6 |
| CC | GO:0044464; cell part | GO:0034719; SMN-Sm protein complex | 4.489E-05 | 4.093E-02 | SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.357E-06 | 4.895E-04 | CYP2D6, CYP1A2, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 5.613E-04 | 1.090E-02 | TP53, MTOR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.108E-04 | 4.264E-03 | CYP1A2, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.963E-04 | 1.090E-02 | TP53, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.049E-03 | 1.126E-02 | TP53, MTOR |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.075E-04 | 1.090E-02 | CYP2D6, CYP1A2 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.169E-03 | 1.126E-02 | TP53, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.917E-04 | 1.126E-02 | CYP1A2, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.654E-03 | 1.412E-02 | CYP2D6, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.833E-03 | 1.412E-02 | TP53, MTOR |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
